Novel treatment for gout using bacteria: The metabolic waste product that cause gout can be removed by ingesting bacteria that optimize the function of the gut microbiome – so called medical nutrition. Recently, the European Innovation Council (EIC) awarded EUR 3,8 mil. to the public-private project, Bugs4Urate, to test a novel urate lowering therapy, BEO 001, in a clinical trial.
Gout is the most common type of arthritis. 4% of the population in the western world suffers from gout and more than 10% are at risk of developing the disease. Gout is caused when the waste product, urate, from the degradation of nucleic acids (e.g. DNA) accumulates in patients’ joints.
The European Innovation Council has granted the Bugs4Urate-project a total of 3,8 million euro, through their prestigious EIC Pathfinder grants. The product, BEO 001, that is at the center of Bugs4Urate project has been developed by Beo Therapeutics. In a joint effort the consortium will test the efficacy and the mode-of-action of the product in two clinical trials that includes 100 patients. In addition, the consortium will investigate how the therapy can be personalized by analyzing the gut microbiome, patients’ diet and genetics.
NeoBioSys, as an expert of bioprocess engineering, has been solicited to develop USP and DSP and produce the clinical product.
The project consortium consists of:
NeoBioSys® was born from the resolve of its two co-founders Nicolas Bourgne and Grégory Chambon to answer the issues of valorization and industrialization of production processes by biotechnology.
Contact us
Navigation
All rights reserved – Neobiosys 2022 – Legal Notice – Created by Coqpit, Digital Agency.
